ENTRY       D11934            Mixture   Drug
NAME        Pertuzumab, trastuzumab and hyaluronidase;
            Pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination);
            Pertuzumab, trastuzumab and hyaluronidase-zzxf;
            Phesgo (TN)
PRODUCT     PHESGO (Genentech)
COMPONENT   Pertuzumab [DR:D05446], Trastuzumab [DR:D03257], Hyaluronidase (human recombinant) [DR:D06604]
REMARK      Therapeutic category: 4291
            ATC code: L01XY02
            Product: D11934<JP/US>
EFFICACY    Antineoplastic
  DISEASE   Breast cancer [DS:H00031]
  TYPE      Monoclonal antibody, combination
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XY Combinations of antineoplastic agents
                 L01XY02 Pertuzumab and trastuzumab
                  D11934  Pertuzumab, trastuzumab and hyaluronidase &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Pertuzumab/ Trastuzumab/ Hyaluronidase
                D11934  Pertuzumab, trastuzumab and hyaluronidase
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11934  Pertuzumab, trastuzumab and hyaluronidase
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11934
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11934
///
